Tidal Investments LLC Sells 1,567 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Tidal Investments LLC trimmed its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 13.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,705 shares of the biotechnology company's stock after selling 1,567 shares during the period. Tidal Investments LLC's holdings in United Therapeutics were worth $3,424,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Park Avenue Securities LLC increased its stake in shares of United Therapeutics by 18.4% in the 4th quarter. Park Avenue Securities LLC now owns 2,614 shares of the biotechnology company's stock worth $922,000 after purchasing an additional 407 shares in the last quarter. Merit Financial Group LLC increased its stake in shares of United Therapeutics by 36.6% in the 4th quarter. Merit Financial Group LLC now owns 3,463 shares of the biotechnology company's stock worth $1,222,000 after purchasing an additional 927 shares in the last quarter. HB Wealth Management LLC purchased a new stake in shares of United Therapeutics in the 4th quarter worth $376,000. UMB Bank n.a. increased its stake in shares of United Therapeutics by 4.9% in the 4th quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company's stock worth $388,000 after purchasing an additional 51 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its stake in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 58 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded up $2.51 during trading on Tuesday, reaching $310.16. 63,344 shares of the stock traded hands, compared to its average volume of 441,248. The company has a market capitalization of $13.99 billion, a price-to-earnings ratio of 13.63, a P/E/G ratio of 0.97 and a beta of 0.58. The business has a fifty day simple moving average of $299.41 and a two-hundred day simple moving average of $336.74. United Therapeutics Co. has a 52-week low of $264.33 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter last year, the firm earned $6.17 EPS. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. On average, research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $300.93, for a total value of $3,310,230.00. Following the completion of the sale, the executive vice president now owns 36,781 shares of the company's stock, valued at $11,068,506.33. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. The trade was a 22.77% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 45,500 shares of company stock valued at $13,447,180. Insiders own 10.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on UTHR shares. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target for the company in a research note on Monday, April 21st. HC Wainwright reiterated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research note on Monday, May 5th. Morgan Stanley increased their price target on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 1st. JPMorgan Chase & Co. cut their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Finally, Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $392.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.